Impax broke U.S. antitrust law by delaying generic drug, jury told

BOSTON (Reuters) - Impax Laboratories Inc went to trial on Monday over allegations by major retailers and consumers that the company agreed to delay launching a generic version of acne medication Solodyn in exchange for millions of dollars from the manufacturer.